Preliminary Safety, Pharmacological and Efficacy Data from Patients with Relapsed or Refractory B-Cell Malignancies Treated with the ICP-248, a Next Generation BCL2 Inhibitor

被引：0

作者：

Yi, Shuhua ^{[1
,2
,3
]}

Jin, Jie ^{[4
]}

Zhou, Keshu ^{[5
]}

Zhu, Huayuan ^{[6
]}

Ma, Kate ^{[7
]}

Jiang, Rili ^{[8
]}

Wang, Weige ^{[8
]}

Zhang, Bin ^{[9
]}

Qiu, Lugui ^{[1
,2
,3
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Inst Hematol, Tianjin, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China

[3] Tianjin Inst Hlth Sci, Tianjin, Peoples R China

[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China

[5] Zhengzhou Univ, Henan Canc Hosp, Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[6] Nanjing Med Univ, Jiangsu Prov Hosp, Affiliated Hosp 1, Dept Hematol, Nanjing, Peoples R China

[7] Beijing InnoCare Pharm Tech Co Ltd, Beijing, Peoples R China

[8] Beijing InnoCare Pharm Tech Co Ltd, Shanghai, Peoples R China

[9] InnoCare Pharma Ltd, Beijing, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-182558

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib
Tam, Constantine S.
Verner, Emma
Lasica, Masa
Arbelaez, Alejandro
Browett, Peter J.
Soumerai, Jacob D.
Hilger, James
Fang, Yiqian
Huang, Jane
Simpson, David
Opat, Stephen
Cheah, Chan Yoon Y.
BLOOD, 2021, 138
[2] PRELIMINARY SAFETY AND EFFICACY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES TREATED WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB-11417 IN MONOTHERAPY OR IN COMBINATION WITH ZANUBRUTINIB
Ghia, P.
Tam, C.
Verner, E.
Lasica, M.
Arbelaez, A.
Browett, P.
Soumerai, J.
Hilger, J.
Fang, Y.
Huang, J.
Simpson, D.
Opat, S.
Cheah, C.
HAEMATOLOGICA, 2022, 107 : 33 - 34
[3] Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
Hamlin, Paul A.
Flinn, Ian W.
Wagner-Johnston, Nina
Burger, Jan A.
Coffey, Greg P.
Conley, Pamela B.
Michelson, Glenn
Leeds, Janet M.
Der, Kenneth
Kim, Yvonne
Sabalvaro-Torres, Alice
Birrell, Matt
Pandey, Anjali
Curnutte, John T.
Patel, Manish R.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (04) : E90 - E93
[4] Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study
de Vos, Sven
Leonard, John P.
Friedberg, Jonathan W.
Zain, Jasmine
Dunleavy, Kieron
Humerickhouse, Rod
Hayslip, John
Pesko, John
Wilson, Wyndham H.
LEUKEMIA & LYMPHOMA, 2021, 62 (04) : 810 - 818
[5] Phase-I Study of the new B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 as Monotherapy or in Combination with Zanubrutinib (zanu) in Patients (pat) with B-Cell Malignancies: preliminary Data
Stilgenbauer, S.
Opat, S.
Cheah, C. Y.
Lasica, M.
Verner, E.
Browett, P. J.
Chan, H.
Soumerai, J. D.
Gonzalez, Barca E.
Hilger, J.
Fang, Y.
Simpson, D.
Tam, C. S.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 30 - 30
[6] Preliminary Safety and Efficacy Of BGB-11417, a Potent and Selective B-Cell Lymphoma 2 (BCL2) Inhibitor, in Patients (Pts) with Acute Myeloid Leukemia (AML)
Shortt, Jake
Platzbecker, Uwe
Tan, Shuh Ying
Cannell, Paul
Ng, Teng Fong
Fong, Chun Yew
Ramanathan, Sundra
Rajagopal, Rajeev
Leitch, Sophie
Gasiorowski, Robin
Grove, Carolyn
Lenton, Douglas
Tan, Peter
Dinardo, Courtney
Ling, Ming Tat
Cheng, Si
Liu, Yuan
Co, Melannie
Chan, Wai Y.
Simpson, David
Wei, Andrew H.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 144 - 144
[7] Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
Zhang, Huilai
Zhou, Keshu
Cheng, Ying
Zhang, Liling
Yang, Haiyan
Zou, Liqun
Cao, Junning
Huang, Huiqiang
Guo, Ye
Wang, Zhao
Huang, Sha
Liang, Zhiyu
Yao, Hui
Guo, Haiyi
Fang, Yiqian
Zhu, Hongjie
BLOOD, 2022, 140 : 3750 - 3751
[8] Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies
Wang, Na
Hu, Xuelian
Cao, Wenyue
Li, Chunrui
Xiao, Yi
Cao, Yang
Gu, Chaojiang
Zhang, Shangkun
Chen, Liting
Cheng, Jiali
Wang, Gaoxiang
Zhou, Xiaoxi
Zheng, Miao
Mao, Xia
Jiang, Lijun
Wang, Di
Wang, Qiuxiang
Lou, Yaoyao
Cai, Haodong
Yan, Dandan
Zhang, Yicheng
Zhang, Tongcun
Zhou, Jianfeng
Huang, Liang
BLOOD, 2020, 135 (01) : 17 - 27
[9] Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients (Pts) with Relapsed/Refractory B-Cell Malignancies
Shadman, Mazyar
Flinn, Ian W.
Levy, Moshe Y.
Porter, Ryan
Burke, John M.
Cultrera, Jennifer L.
Misleh, Jamal
Zafar, Syed F.
Freeman, Benjamin
Rao, Subramanya S.
Yimer, Habte
Chaudhry, Arvind
Gandhi, Mitul D.
Guthrie, Troy H.
Kingsley, Edwin
Tumula, Praveen K.
Manda, Sudhir
Chen, Dih-Yih
Cohen, Aileen
By, Kunthel
Xu, Linlin
Liu, Ye
Sharman, Jeff P.
BLOOD, 2021, 138
[10] Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Qin, Yan
He, Xiaohui
Yang, Sheng
Liu, Peng
Zhou, Shengyu
Yang, Jianliang
Gui, Lin
Zhong, Qiaofeng
Zhao, Fengyi
Shi, Yuankai
Jing, Hongmei
Zhang, Shiyue
Guo, Ruihan
Shi, Yuankai
BLOOD, 2021, 138

← 1 2 3 4 5 →